|
FDA authorizes additional oral antiviral for treatment of COVID-19 in certain adults
|
27 December 2021 |
|
FDA authorizes first oral antiviral for treatment of COVID-19
|
22 December 2021 |
|
FDA expands eligibility for Pfizer-BioNTech COVID-19 booster dose to 16- and 17-year-olds
|
09 December 2021 |
|
FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age
|
29 October 2021 |
|
FDA, NIH, and 15 private organizations join forces to increase effective gene therapies for rare diseases
|
28 October 2021 |
|
FDA takes additional actions on the use of a booster dose for COVID-19 vaccines
|
21 October 2021 |
|
FDA awards 11 grants to clinical trials to develop new medical products for rare disease treatments
|
14 October 2021 |
|
FDA approves innovative treatment for pediatric patients with congenital athymia
|
08 October 2021 |
|
FDA authorizes software that can help identify prostate cancer
|
21 September 2021 |
|
FDA advances data, IT modernization efforts with new office of digital transformation
|
15 September 2021 |
|
FDA approves first COVID-19 vaccine
|
24 August 2021 |
|
FDA approves new treatment for Pompe disease
|
06 August 2021 |
|
FDA approves first interchangeable biosimilar insulin product for treatment of diabetes
|
29 July 2021 |
|
FDA approves first oral blood thinning medication for children
|
22 June 2021 |
|
FDA grants accelerated approval for Alzheimer's drug
|
09 June 2021 |
|
FDA approves new drug treatment for chronic weight management, first since 2014
|
04 June 2021 |
|
FDA authorizes additional monoclonal antibody for treatment of COVID-19
|
28 May 2021 |
|
FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents in another important action in fight against pandemic
|
11 May 2021 |
|
FDA and CDC lift recommended pause on Johnson & Johnson (Janssen) COVID-19 vaccine use following thorough safety review
|
23 April 2021 |
|
FDA revokes emergency use authorization for monoclonal antibody Bamlanivimab
|
16 April 2021 |